论文部分内容阅读
通过测量胰腺癌裸鼠模型瘤内注射 1 2 5I-Ud R后各脏器的放射性活度 ,以及观察用药后瘤体外观和荷瘤鼠生存率的变化 ,分析 1 2 5I-Ud R在生物体内的药物分布规律和治疗效果。实验结果表明 ,1 2 5I-Ud R局部注射后可在瘤内持续浓聚 ,瘤内放射性浓度可达其他脏器的 1 0 3～ 93 1倍 ,聚集在瘤内的 1 2 5I-Ud R可致肿瘤细胞坏死 ,接受治疗的荷瘤鼠生存期明显长于 Na1 2 5I对照组 (χ2 =7.66,P <0 .0 1 )和空白对照组 (χ2 =8.49,P <0 .0 1 )。
By measuring the radioactivity of various organs after intratumoral injection of 125I-UdR in pancreatic cancer nude mice models, and observing the tumor appearance and the survival rate of tumor-bearing mice after the administration, the changes of 125I-UdR in biological In vivo drug distribution and treatment. The experimental results show that after 125I-Ud R local injection can continue to accumulate in the tumor, the tumor radioactive concentrations of up to 103 ~ 93 times other organs, gathered in the tumor of 125I-UdR Can cause tumor cell necrosis. The survival time of the treated tumor bearing mice was significantly longer than that of the Na1 2 5I control group (χ2 = 7.66, P <0.01) and the blank control group (χ2 = 8.49, P <0.01).